A detailed history of Wells Fargo & Company transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 200,820 shares of NTLA stock, worth $2.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200,820
Previous 201,657 0.42%
Holding current value
$2.87 Million
Previous $4.51 Million 8.58%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$19.72 - $27.36 $16,505 - $22,900
-837 Reduced 0.42%
200,820 $4.13 Million
Q2 2024

Aug 13, 2024

SELL
$20.02 - $27.22 $282,302 - $383,829
-14,101 Reduced 6.54%
201,657 $4.51 Million
Q1 2024

May 10, 2024

BUY
$23.82 - $32.8 $313,566 - $431,779
13,164 Added 6.5%
215,758 $5.94 Million
Q4 2023

Feb 09, 2024

SELL
$23.16 - $32.34 $564,525 - $788,287
-24,375 Reduced 10.74%
202,594 $6.18 Million
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $1.25 Million - $1.81 Million
39,566 Added 21.11%
226,969 $7.18 Million
Q2 2023

Aug 15, 2023

BUY
$34.58 - $46.03 $830,023 - $1.1 Million
24,003 Added 14.69%
187,403 $7.64 Million
Q1 2023

May 12, 2023

BUY
$33.3 - $44.82 $3.11 Million - $4.18 Million
93,314 Added 133.14%
163,400 $6.09 Million
Q4 2022

Feb 13, 2023

SELL
$33.21 - $62.69 $462,880 - $873,773
-13,938 Reduced 16.59%
70,086 $2.45 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $497,358 - $661,360
9,224 Added 12.33%
84,024 $4.7 Million
Q2 2022

Aug 12, 2022

SELL
$38.49 - $76.21 $936,923 - $1.86 Million
-24,342 Reduced 24.55%
74,800 $3.87 Million
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $1.75 Million - $3.57 Million
-30,021 Reduced 23.24%
99,142 $7.21 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $70,532 - $96,852
700 Added 0.54%
129,163 $15.3 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $1.84 Million - $2.46 Million
13,899 Added 12.13%
128,463 $17.2 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $691,048 - $1.84 Million
-11,351 Reduced 9.01%
114,564 $18.6 Million
Q1 2021

May 13, 2021

SELL
$46.59 - $83.68 $1.34 Million - $2.41 Million
-28,846 Reduced 18.64%
125,915 $10.1 Million
Q4 2020

Feb 09, 2021

BUY
$18.83 - $63.53 $1.66 Million - $5.6 Million
88,173 Added 132.42%
154,761 $8.42 Million
Q3 2020

Nov 05, 2020

SELL
$17.47 - $24.93 $764,958 - $1.09 Million
-43,787 Reduced 39.67%
66,588 $1.32 Million
Q2 2020

Aug 13, 2020

BUY
$11.14 - $22.87 $330,278 - $678,049
29,648 Added 36.73%
110,375 $2.32 Million
Q1 2020

May 14, 2020

BUY
$9.44 - $15.58 $762,062 - $1.26 Million
80,727 New
80,727 $988,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.